Sobi Submits Application For Orfadin(R) Oral Suspension To FDA

STOCKHOLM, Sweden, Oct. 29, 2013 (GLOBE NEWSWIRE) --
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company'sapplication for Orfadin oral suspension has been submitted to the US Food andDrug Administration (FDA). This new dosage form has been developed to facilitatethe ease and accuracy of administration for Orfadin in paediatric patients aswell as to increase convenience for patients and their caregivers.About OrfadinOrfadin is used for the treatment of hereditary tyrosinemia type 1 (HT-1), arare genetic disorder which can cause liver failure, kidney dysfunction andneurological problems.About SobiSobi is an international specialty healthcare company dedicated to rarediseases. Our mission is to develop and deliver innovative therapies andservices to improve the lives of patients. The product portfolio is primarilyfocused on inflammation and genetic diseases, with three late stage biologicaldevelopment projects within haemophilia and neonatology. We also market aportfolio of specialty and rare disease products for partner companies. Sobi isa pioneer in biotechnology with world-class capabilities in protein biochemistryand biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMXStockholm. More information is available at more information - not for publicationMedia relations            Investor relationsOskar Bosson, Head of      Jörgen Winroth, Vice President, Head of InvestorCommunications             RelationsT: +46 70 410 71 80        T: +1 347-224-0819, +1 212-579-0506, +46 8 697      jorgen.winroth@sobi.comSobi submits application for Orfadin® oral suspension to FDA:[HUG#1738708]